In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
Browsing: Taxonomy > Clinical trials
Researchers have demonstrated that taking a high dose of esomeprazole (Nexium®) along with a low dose aspirin, for at least 7 years, can reduce the risk of develop a high-grade dyslplasia or esophageal cancer.
The PRODIGE 7 randomized study has demonstrated that for advanced colorectal cancer patients, hyperthermic intra-peritoneal chemotherapy delivered to the abdomen during surgery, may not be necessary.
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
A Phase III trial presented at ASCO has suggested that surgery might not be a necessity for patients suffering from advanced kidney cancer.
The Phase III TAILORx clinical trial results indicate that most women with a specific early-stage breast cancer and midrange score on a gene expression assay do not need chemotherapy after surgery.
A novel chemotherapy strategy has improved cure rates for a rare cancer of the muscle tissue, termed rhabdomyosarcoma.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
Interim blinded survival data has been released from the Phase III clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma patients; early findings from the 11-year study involving more than 300 people worldwide demonstrates promising survival results
AstraZeneca and MedImmune have announced results of their Phase III PACIFIC trial.